Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Wolfgang WickHoward A Fine

Abstract

This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) or lomustine (100 to 130 mg/m(2), day 1). Assuming a 45% improvement in progression-free survival (PFS), 397 patients were required to provide 80% power to achieve statistical significance at a one-sided level of .025. Enrollment was terminated at 266 patients (enzastaurin, n = 174; lomustine, n = 92) after a planned interim analysis for futility. Patient characteristics were balanced between arms. Median PFS (1.5 v 1.6 months; hazard ratio [HR] = 1.28; 95% CI, 0.97 to 1.70), overall survival (6.6 v 7.1 months; HR = 1.20; 95% CI, 0.88 to 1.65), and 6-month PFS rate (P = .13) did not differ significantly between enzastaurin and lomustine, respectively. Stable disease occurred in 38.5% and 35.9% of patients and objective response occurred in 2.9% and 4.3% of patients, respectively. Time to deterioration of physical and functional well-being and symptoms did not differ between arms (HR = 1.12; P = .54). Four patients discontinued enzastaurin because of drug-related se...Continue Reading

Associated Clinical Trials

References

Sep 1, 1977·Journal of Neurosurgery·V A LevinC B Wilson
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Aug 15, 1997·European Journal of Biochemistry·E Livneh, D D Fishman
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Yung
Feb 22, 2002·Cancer Chemotherapy and Pharmacology·Beverly A TeicherMargaret M Faul
Feb 1, 2003·Lancet·Anthony BehinJean-Yves Delattre
Feb 13, 2003·Brain Pathology·Paul S Mischel, Timothy F Cloughesy
Nov 1, 2003·Cancer Chemotherapy and Pharmacology·Kristan A KeyesBeverly A Teicher
Nov 26, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy N RichHenry S Friedman
Jan 28, 2004·Cancer·Susan M ChangMichael D Prados
Apr 15, 2004·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Mark A RosenthalLawrence Cher
Oct 22, 2004·Seminars in Oncology·Stuart A Grossman, Julette F Batara
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Lisa M DeAngelis
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciRoy S Herbst
Jan 11, 2007·Annals of Neurology·Ghazaleh TabatabaiWolfgang Wick
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J VredenburghHenry S Friedman
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antje WickWolfgang Wick
Nov 29, 2007·Expert Opinion on Investigational Drugs·Elizabeth R GerstnerTracy T Batchelor
Oct 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric RaymondUNKNOWN European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Nov 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David A ReardonL Burt Nabors
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
May 26, 2009·Seminars in Radiation Oncology·Teri N Kreisl
Feb 13, 2010·Neuro-oncology·Teri N KreislHoward A Fine

❮ Previous
Next ❯

Citations

Aug 3, 2010·Der Nervenarzt·W Wick, M Weller
Mar 29, 2011·Cancer Chemotherapy and Pharmacology·Athanassios P Kyritsis, Victor A Levin
Sep 4, 2013·Journal of Industrial Microbiology & Biotechnology·Lesley-Ann Giddings, David J Newman
Feb 1, 2011·Current Neurology and Neuroscience Reports·Wolfgang WickMichael Weller
Feb 19, 2013·Current Treatment Options in Neurology·Jennie Taylor, Elizabeth R Gerstner
May 21, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Nicholas Butowski
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew S ChiPatrick Y Wen
Apr 3, 2013·Oncogenesis·T ForshewP J Mulholland
Jul 31, 2012·Japanese Journal of Clinical Oncology·Motoo NaganeMasao Matsutani
Apr 16, 2013·Japanese Journal of Clinical Oncology·Yoshitaka Narita
May 28, 2010·Neuro-oncology·Benjamin BergerMarkus Weiler
Jun 4, 2011·Neuro-oncology·Wolfgang WickMichael Platten
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Feb 1, 2012·The Cancer Journal·Jiangbing ZhouW Mark Saltzman
Feb 1, 2012·The Cancer Journal·Jethro Hu, Santosh Kesari
Oct 6, 2010·Future Oncology·Michael WellerGhazaleh Tabatabai
Oct 14, 2011·Future Oncology·Mersiha HadziahmetovicArnab Chakravarti
Jun 10, 2011·Current Oncology·J C EasawUNKNOWN Canadian Glioblastoma Recommendations Committee
Sep 1, 2012·CNS Oncology·Sean A Grimm, Marc C Chamberlain
Feb 11, 2014·Current Oncology Reports·Mohamed Ali Hamza, Mark Gilbert
Apr 29, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·M AjazA Chalmers
May 16, 2014·Neuro-oncology·Roger Stupp, Michael Weller
May 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StuppUNKNOWN ESMO Guidelines Working Group
Jul 6, 2014·Journal of Neuro-oncology·Manmeet S Ahluwalia, Susan M Chang
Apr 16, 2014·Neuro-oncology·Marc C Chamberlain
Sep 1, 2014·Seminars in Oncology·Linda DirvenMartin J B Taphoorn
Sep 24, 2010·Acta Neuropathologica·Ghazaleh TabatabaiMichael Weller
Nov 5, 2014·CNS Oncology·Isabel Arrillaga-Romany, Andrew D Norden
Jun 3, 2015·Neuro-oncology Practice·Hans-Georg WirschingGhazaleh Tabatabai
Nov 19, 2014·CNS Drugs·Riccardo SoffiettiRoberta Rudà
Jan 15, 2015·Neurosurgical Focus·Brandyn A Castro, Manish K Aghi
Dec 2, 2014·Neurosurgical Focus·Darryl LauManish K Aghi
Oct 16, 2014·Neuro-oncology·Howard A Fine

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Henry S FriedmanTimothy F Cloughesy
The New England Journal of Medicine
Roger StuppNational Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
James J VredenburghHenry S Friedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Teri N KreislHoward A Fine
© 2021 Meta ULC. All rights reserved